(Q50966333)

English

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

scientific article published on 10 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. (English)

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

0 references

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Tanja D de Gruijl

15

object named as

Tanja D de Gruijl

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

author name string

Alfons J M van den Eertwegh

1

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Jurjen Versluis

2

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

H Pieter van den Berg

3

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Saskia J A M Santegoets

4

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

R Jeroen A van Moorselaar

5

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Tim M van der Sluis

6

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Helen E Gall

7

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Thomas C Harding

8

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Karin Jooss

9

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Israel Lowy

10

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Herbert M Pinedo

11

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Rik J Scheper

12

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Anita G M Stam

13

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

B Mary E von Blomberg

14

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Kristen Hege

16

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Natalie Sacks

17

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Winald R Gerritsen

18

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

publication date

10 February 2012

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

13

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

5

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

509-517

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Current status of immunological therapies for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The emerging role of CTLA-4 as an immune attenuator

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved endpoints for cancer immunotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate cancer as a model for tumour immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70007-4

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

1 reference

Europe PubMed Central

26 March 2018

http://europepmc.org/abstract/MED/22326922

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50966333&oldid=1790655003"